Cross-Sector entity
Every one of those 1 sits in a single category, funding. Ibogaine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. PsyLabs Ltd. appears in 1 tracked Cross-Sector story from February 21, 2026.
1 verified story tracked
Last mentioned: Feb 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. Ibogaine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. PsyLabs Ltd. appears in 1 tracked Cross-Sector story from February 21, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PsyLabs Ltd.. Shared-story counts are live from our verified record — not editorial picks.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.
